interferon beta 1-a

DRUG2 trials

Sponsors

Fred Lublin, Biogen

Conditions

Relapsing Remitting Multiple Sclerosis

Phase 2

Treatment Interruption of Natalizumab

CompletedNCT01071083

BiogenRelapsing Remitting Multiple Sclerosis

Start: 2010-03-31End: 2011-11-30Updated: 2013-09-19

Phase 3

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx

CompletedNCT00211887

Fred LublinRelapsing Remitting Multiple Sclerosis

Start: 2005-01-31End: 2013-03-31Updated: 2014-04-03

Related Papers

Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.

2024-04-2222 citations

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset

Multiple Sclerosis Journal2023-10-1314 citations

Predictors of Disease Activity and Worsening in Relapsing-Remitting Multiple Sclerosis

Neurology Clinical Practice2022-05-2312 citations

Early first‐line treatment response and subsequent disability worsening in relapsing–remitting multiple sclerosis

European Journal of Neurology2021-12-202 citations

Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.

2021-08-2533 citations

Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.

2021-08-1025 citations

The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing–Remitting Multiple sclerosis: A CombiRx Secondary Analysis

Journal of Central Nervous System Disease2021-01-016 citations